BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67 Suppl 1:5-16. [PMID: 20340012 DOI: 10.1007/s00228-009-0782-9] [Cited by in Crossref: 136] [Cited by in F6Publishing: 115] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Petri KC, Jacobsen LV, Klein DJ. Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis. Clin Pharmacokinet 2015;54:663-70. [PMID: 25603819 DOI: 10.1007/s40262-014-0229-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
2 Mian P, Valkenburg AJ, Allegaert K, Koch BCP, Breatnach CV, Knibbe CAJ, Tibboel D, Krekels EHJ. Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass. J Clin Pharmacol 2019;59:847-55. [PMID: 30633373 DOI: 10.1002/jcph.1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Antimicrob Agents Chemother 2015;59:6344-51. [PMID: 26248375 DOI: 10.1128/AAC.01157-15] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 5.2] [Reference Citation Analysis]
4 De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014;31:754-67. [PMID: 24065592 DOI: 10.1007/s11095-013-1197-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
5 Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children. J Acquir Immune Defic Syndr 2014;67:277-86. [PMID: 25140906 DOI: 10.1097/QAI.0000000000000300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
6 Barrett JS, Barrett RF, Vinks AA. Status Toward the Implementation of Precision Dosing in Children. J Clin Pharmacol 2021;61 Suppl 1:S36-51. [PMID: 34185896 DOI: 10.1002/jcph.1830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu XI, Dallmann A, Wang YM, Green DJ, Burnham JM, Chiang B, Wu P, Sheng M, Lu K, van den Anker JN, Burckart GJ. Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. J Clin Pharmacol 2019;59:1130-43. [PMID: 30865317 DOI: 10.1002/jcph.1406] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
8 Coppini R, Simons SHP, Mugelli A, Allegaert K. Clinical research in neonates and infants: Challenges and perspectives. Pharmacol Res 2016;108:80-7. [PMID: 27142783 DOI: 10.1016/j.phrs.2016.04.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
9 Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology. International Journal of Pharmaceutics 2013;452:8-13. [DOI: 10.1016/j.ijpharm.2012.03.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
10 Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol 2015;79:395-404. [PMID: 25855821 DOI: 10.1111/bcp.12267] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 13.8] [Reference Citation Analysis]
11 Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J 2015;34:e63-70. [PMID: 25742090 DOI: 10.1097/INF.0000000000000603] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
12 Kleiber N, Tromp K, Mooij MG, van de Vathorst S, Tibboel D, de Wildt SN. Ethics of drug research in the pediatric intensive care unit. Paediatr Drugs 2015;17:43-53. [PMID: 25354987 DOI: 10.1007/s40272-014-0101-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
13 Matera MG, Rinaldi B, Calzetta L, Cazzola M. Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. Expert Opin Drug Metab Toxicol 2017;13:129-36. [PMID: 27615145 DOI: 10.1080/17425255.2017.1234604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 De Rose DU, Cairoli S, Dionisi M, Santisi A, Massenzi L, Goffredo BM, Dionisi-Vici C, Dotta A, Auriti C. Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age. Int J Mol Sci 2020;21:E5898. [PMID: 32824472 DOI: 10.3390/ijms21165898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
15 Raffaeli G, Pokorna P, Allegaert K, Mosca F, Cavallaro G, Wildschut ED, Tibboel D. Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge. Front Pediatr 2019;7:360. [PMID: 31552205 DOI: 10.3389/fped.2019.00360] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
16 Zhao W, Le Guellec C, Benjamin DK Jr, Hope WW, Bourgeois T, Watt KM, van den Anker JN, Matrot B, Saxen H, Hoppu K, Manzoni P, Jacqz-Aigrain E. First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin Pharmacokinet 2014;53:1005-18. [PMID: 25154507 DOI: 10.1007/s40262-014-0169-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
17 Allegaert K, Naulaers G. Haemodynamics of intravenous paracetamol in neonates. Eur J Clin Pharmacol. 2010;66:855-858. [PMID: 20607221 DOI: 10.1007/s00228-010-0860-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
18 Zhao W, Piana C, Danhof M, Burger D, Della Pasqua O, Jacqz-Aigrain E. Population pharmacokinetics of abacavir in infants, toddlers and children. Br J Clin Pharmacol 2013;75:1525-35. [PMID: 23126277 DOI: 10.1111/bcp.12024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
19 Russo FM, Mian P, Krekels EH, Van Calsteren K, Tibboel D, Deprest J, Allegaert K. Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. Xenobiotica 2019;49:98-105. [PMID: 29278046 DOI: 10.1080/00498254.2017.1422217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Smits A, Kulo A, van den Anker J, Allegaert K. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol 2017;13:157-66. [PMID: 27623706 DOI: 10.1080/17425255.2017.1234606] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
21 Masters JC, Barry E, Knight B. Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Pharmacokinet 2019;58:271-82. [PMID: 30022367 DOI: 10.1007/s40262-018-0694-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Ketharanathan N, Yamamoto Y, Rohlwink U, Wildschut ED, Hunfeld M, de Lange ECM, Tibboel D. Analgosedation in paediatric severe traumatic brain injury (TBI): practice, pitfalls and possibilities. Childs Nerv Syst 2017;33:1703-10. [PMID: 29149387 DOI: 10.1007/s00381-017-3520-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Thompson EJ, Wu H, Melloni C, Balevic S, Sullivan JE, Laughon M, Clark KM, Kalra R, Mendley S, Payne EH, Erinjeri J, Gelber CE, Harper B, Cohen-Wolkowiez M, Hornik CP; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Doxycycline in Children. Antimicrob Agents Chemother 2019:AAC. [PMID: 31548185 DOI: 10.1128/AAC.01508-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 2012;59:1147-65. [PMID: 23036249 DOI: 10.1016/j.pcl.2012.07.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
25 Völler S, Flint RB, Stolk LM, Degraeuwe PLJ, Simons SHP, Pokorna P, Burger DM, de Groot R, Tibboel D, Knibbe CAJ; DINO study group. Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. Eur J Pharm Sci 2017;109S:S90-7. [PMID: 28506869 DOI: 10.1016/j.ejps.2017.05.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
26 Baverel PG, Jain M, Stelmach I, She D, Agoram B, Sandbach S, Piper E, Kuna P. Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. Br J Clin Pharmacol 2015;80:1337-49. [PMID: 26182954 DOI: 10.1111/bcp.12725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
27 Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, Boelens JJ, Knibbe CA. Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet 2015;54:435-46. [PMID: 25466602 DOI: 10.1007/s40262-014-0214-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
28 Deferm N, Annink KV, Faelens R, Schroth M, Maiwald CA, Bakkali LE, van Bel F, Benders MJNL, van Weissenbruch MM, Hagen A, Smits A, Annaert P, Franz AR, Allegaert K; ALBINO Study Group. Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance. Clin Pharmacokinet 2021;60:897-906. [PMID: 33611729 DOI: 10.1007/s40262-021-00991-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Medellín-Garibay SE, Rueda-Naharro A, Peña-Cabia S, García B, Romano-Moreno S, Barcia E. Population pharmacokinetics of gentamicin and dosing optimization for infants. Antimicrob Agents Chemother 2015;59:482-9. [PMID: 25385111 DOI: 10.1128/AAC.03464-14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
30 Admiraal R, van Kesteren C, Boelens JJ, Bredius RGM, Tibboel D, Knibbe CAJ. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 2014;99:267-72. [DOI: 10.1136/archdischild-2013-303721] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
31 Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth 2014;24:30-8. [PMID: 23617305 DOI: 10.1111/pan.12176] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
32 de Castro FA, Piana C, Simões BP, Lanchote VL, Della Pasqua O. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. Br J Clin Pharmacol 2015;80:618-29. [PMID: 25819742 DOI: 10.1111/bcp.12648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Dubrocq G, Rakhmanina N, Phelps BR. Challenges and Opportunities in the Development of HIV Medications in Pediatric Patients. Paediatr Drugs 2017;19:91-8. [PMID: 28074348 DOI: 10.1007/s40272-016-0210-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
35 van der Aa MP, Elst MA, van Mil EG, Knibbe CA, van der Vorst MM. METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. Trials. 2014;15:207. [PMID: 24899137 DOI: 10.1186/1745-6215-15-207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
36 Krekels EH, van Ham S, Allegaert K, de Hoon J, Tibboel D, Danhof M, Knibbe CA. Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. Eur J Clin Pharmacol 2015;71:1075-82. [PMID: 26139379 DOI: 10.1007/s00228-015-1887-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
37 Krekels EHJ, Tibboel D, Danhof M, Knibbe CAJ. Prediction of Morphine Clearance in the Paediatric Population: How Accurate are the Available Pharmacokinetic Models? Clin Pharmacokinet 2012;51:695-709. [DOI: 10.1007/s40262-012-0006-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Smits A, van den Anker JN, Allegaert K. Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use. J Pharm Pharmacol 2017;69:350-60. [PMID: 27364566 DOI: 10.1111/jphp.12599] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
39 Roth WJ, Kissinger CB, McCain RR, Cooper BR, Marchant-Forde JN, Vreeman RC, Hannou S, Knipp GT. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS J 2013;15:763-74. [PMID: 23595360 DOI: 10.1208/s12248-013-9482-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
40 Baarslag MA, Allegaert K, Knibbe CAJ, van Dijk M, Tibboel D. Pharmacological sedation management in the paediatric intensive care unit. Journal of Pharmacy and Pharmacology 2017;69:498-513. [DOI: 10.1111/jphp.12630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
41 Michaličková D, Pokorná P, Tibboel D, Slanař O, Knibbe CAJ, Krekels EHJ. Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. Pediatr Crit Care Med 2020;21:e707-15. [PMID: 32639476 DOI: 10.1097/PCC.0000000000002402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol 2015;11:1041-52. [PMID: 25958820 DOI: 10.1517/17425255.2015.1046433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
43 Kulo A, de Hoon JN, Allegaert K. The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. Int J Pharm 2012;435:112-4. [PMID: 22641171 DOI: 10.1016/j.ijpharm.2012.05.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
44 Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach. J Biomed Biotechnol. 2012;2012:103763. [PMID: 22500073 DOI: 10.1155/2012/103763] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
45 Hampson LV, Herold R, Posch M, Saperia J, Whitehead A. Bridging the gap: a review of dose investigations in paediatric investigation plans. Br J Clin Pharmacol 2014;78:898-907. [PMID: 24720849 DOI: 10.1111/bcp.12402] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
46 Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker JN. Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clin Pharmacokinet 2016;55:107-19. [PMID: 26201306 DOI: 10.1007/s40262-015-0301-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
47 Flint RB, Simons SHP, Andriessen P, Liem KD, Degraeuwe PLJ, Reiss IKM, Ter Heine R, Engbers AGJ, Koch BCP, Groot R, Burger DM, Knibbe CAJ, Völler S; DINO Research Group. The bioavailability and maturing clearance of doxapram in preterm infants. Pediatr Res 2021;89:1268-77. [PMID: 32698193 DOI: 10.1038/s41390-020-1037-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Song L, He CY, Yin NG, Liu F, Jia YT, Liu Y. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants. Oncotarget 2017;8:105211-21. [PMID: 29285245 DOI: 10.18632/oncotarget.22114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
49 Palić S, Bhairosing P, Beijnen JH, Dorlo TPC. Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation. Antimicrob Agents Chemother 2019;63:e02507-18. [PMID: 31036692 DOI: 10.1128/AAC.02507-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
50 Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia: Jo urnal of Clinical Pharmacology. The Journal of Clinical Pharmacology 2017;57:345-55. [DOI: 10.1002/jcph.809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
51 van den Anker J, Allegaert K. Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach. Expert Rev Clin Pharmacol. 2012;5:5-8. [PMID: 22142152 DOI: 10.1586/ecp.11.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
52 De Bruyne P, De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Vande Walle J. Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr 2014;173:223-8. [DOI: 10.1007/s00431-013-2108-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
53 De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res 2014;31:2643-54. [PMID: 24789450 DOI: 10.1007/s11095-014-1361-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
54 Krekels EHJ, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, Danhof M, Knibbe CAJ. Evidence-Based Morphine Dosing for Postoperative Neonates and Infants. Clin Pharmacokinet 2014;53:553-63. [DOI: 10.1007/s40262-014-0135-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
55 Kulo A, Smits A, Naulaers G, de Hoon J, Allegaert K. Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation. Daru 2012;20:5. [PMID: 23230503 DOI: 10.1186/1560-8115-20-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Brussee JM, Calvier EA, Krekels EH, Välitalo PA, Tibboel D, Allegaert K, Knibbe CA. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol 2016;9:1235-44. [PMID: 27269200 DOI: 10.1080/17512433.2016.1198256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
57 Zhao W, Leroux S, Biran V, Jacqz-Aigrain E. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. Br J Clin Pharmacol 2018;84:997-1005. [PMID: 29377228 DOI: 10.1111/bcp.13526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
58 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
59 Girardi A, Raschi E, Galletti S, Poluzzi E, Faldella G, Allegaert K, De Ponti F. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf 2015;38:535-51. [PMID: 25863473 DOI: 10.1007/s40264-015-0288-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
60 Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, Peck R, Reigner B. Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children. Clin Pharmacol Ther 2016;100:761-9. [PMID: 27530217 DOI: 10.1002/cpt.449] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
61 Allegaert K, Simons SHP, Tibboel D, Krekels EH, Knibbe CA, van den Anker JN. Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. Eur J Pharm Sci 2017;109S:S27-31. [PMID: 28506866 DOI: 10.1016/j.ejps.2017.05.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
62 Baek YH, Shin JY. Trends in polypharmacy over 12 years and changes in its social gradients in South Korea. PLoS One 2018;13:e0204018. [PMID: 30226885 DOI: 10.1371/journal.pone.0204018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
63 Rodrigues C, Chiron C, Ounissi M, Dulac O, Gaillard S, Nabbout R, Jullien V. Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data. Epilepsy Res 2019;150:38-45. [PMID: 30639958 DOI: 10.1016/j.eplepsyres.2019.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Piana C, Danhof M, Della Pasqua O. Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research. Br J Clin Pharmacol 2014;78:145-57. [PMID: 24433411 DOI: 10.1111/bcp.12322] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
65 Gomeni R, Bressolle-Gomeni F, Spencer TJ, Faraone SV, Fang L, Babiskin A. Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD. Clin Pharmacol Ther 2017;102:951-60. [PMID: 28369788 DOI: 10.1002/cpt.684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol 2016;12:367-75. [PMID: 26817821 DOI: 10.1517/17425255.2016.1147559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
67 Krekels EH, Tibboel D, Knibbe CA. Pediatric pharmacology: current efforts and future goals to improve clinical practice. Expert Opin Drug Metab Toxicol 2015;11:1679-82. [PMID: 26166262 DOI: 10.1517/17425255.2015.1065815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
68 Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. Br J Clin Pharmacol 2013;75:1068-80. [PMID: 23148919 DOI: 10.1111/j.1365-2125.2012.04406.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
69 Krekels EHJ, Knibbe CAJ. Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. Handb Exp Pharmacol 2020;261:231-55. [PMID: 31598838 DOI: 10.1007/164_2019_250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, de Wildt SN, Offringa M. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child 2018;103:695-702. [PMID: 29674514 DOI: 10.1136/archdischild-2017-314506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
71 Ber J, Wiczling P, Hołysz M, Klupczyńska A, Bartkowska-Śniatkowska A, Bieda K, Smuszkiewicz P, Nowicka M, Żurański Ł, Sobczyński P, Matysiak J, Grześkowiak E, Bienert A. Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. J Clin Pharmacol 2020;60:1461-73. [PMID: 32500578 DOI: 10.1002/jcph.1647] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Allegaert K, Tibboel D, van den Anker J. Pharmacological treatment of neonatal pain: in search of a new equipoise. Semin Fetal Neonatal Med 2013;18:42-7. [PMID: 23107602 DOI: 10.1016/j.siny.2012.10.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
73 Knebel W, Rogers J, Polhamus D, Ermer J, Gastonguay MR. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD. J Pharmacokinet Pharmacodyn 2015;42:45-65. [PMID: 25373474 DOI: 10.1007/s10928-014-9397-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
74 Valeur KS, Holst H, Allegaert K. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. Pharmaceut Med 2018;32:251-8. [PMID: 30174435 DOI: 10.1007/s40290-018-0243-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
75 Ye PP, Zheng Y, Du B, Liu XT, Tang BH, Kan M, Zhou Y, Hao GX, Huang X, Su LQ, Wang WQ, Yu F, Zhao W. First dose in neonates: pharmacokinetic bridging study from juvenile mice to neonates for drugs metabolized by CYP3A. Xenobiotica 2020;50:1275-84. [PMID: 32400275 DOI: 10.1080/00498254.2020.1768454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Himebauch AS, Zuppa A. Methods for pharmacokinetic analysis in young children. Expert Opinion on Drug Metabolism & Toxicology 2014;10:497-509. [DOI: 10.1517/17425255.2014.885502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
77 Kos MK, Miksić M, Jovanović M, Roškar R, Grosek Š, Grabnar I. Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. Eur J Pharm Sci 2020;141:105095. [PMID: 31626965 DOI: 10.1016/j.ejps.2019.105095] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Cella M, Kloprogge F, Danhof M, Della Pasqua O. Dosing Rationale for Fixed-Dose Combinations in Children: Shooting From the Hip? Clin Pharmacol Ther 2012;91:718-25. [DOI: 10.1038/clpt.2011.297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
79 Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O. A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. Br J Clin Pharmacol 2014;77:852-60. [PMID: 24118047 DOI: 10.1111/bcp.12246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
80 Allegaert K, van den Anker JN. Clinical pharmacology in neonates: small size, huge variability. Neonatology 2014;105:344-9. [PMID: 24931327 DOI: 10.1159/000360648] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
81 Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect. 2020;8:e00684. [PMID: 33231929 DOI: 10.1002/prp2.684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Clyburne-Sherin AV, Thurairajah P, Kapadia MZ, Sampson M, Chan WW, Offringa M. Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews. Trials 2015;16:417. [PMID: 26385379 DOI: 10.1186/s13063-015-0954-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
83 Offringa M, van der Lee H. Small sample approach, and statistical and epidemiological aspects. Handb Exp Pharmacol 2011;205:181-202. [PMID: 21882112 DOI: 10.1007/978-3-642-20195-0_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
84 Germovsek E, Barker CIS, Sharland M, Standing JF. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clin Pharmacokinet 2019;58:39-52. [PMID: 29675639 DOI: 10.1007/s40262-018-0659-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
85 Ali M, Tins J, Burckhardt BB; on behalf of LENA Consortium. Fit-for-Purpose Quality Control System in Continuous Bioanalysis During Long-Term Pediatric Studies. AAPS J 2019;21. [DOI: 10.1208/s12248-019-0375-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
86 Völler S, Flint RB, Andriessen P, Allegaert K, Zimmermann LJI, Liem KD, Koch BCP, Simons SHP, Knibbe CAJ; DINO study group. Rapidly maturing fentanyl clearance in preterm neonates. Arch Dis Child Fetal Neonatal Ed 2019;104:F598-603. [PMID: 31498775 DOI: 10.1136/archdischild-2018-315920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
87 Ketharanathan N, Yamamoto Y, Rohlwink UK, Wildschut ED, Mathôt RAA, de Lange ECM, de Wildt SN, Argent AC, Tibboel D, Figaji AA. Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy? J Neurotrauma 2019;36:111-7. [PMID: 30019622 DOI: 10.1089/neu.2017.5588] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
88 Zeilmaker GA, Pokorna P, Mian P, Wildschut ED, Knibbe CAJ, Krekels EHJ, Allegaert K, Tibboel D. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. Expert Opin Drug Metab Toxicol 2018;14:417-28. [PMID: 29623729 DOI: 10.1080/17425255.2018.1461836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
89 Leroux S, Elie V, Zhao W, Magreault S, Jacqz-aigrain E. Principles and applications of pharmacometrics in drug evaluation in children. Therapies 2018;73:165-70. [DOI: 10.1016/j.therap.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kontou A, Sarafidis K, Roilides E. Antimicrobial dosing in neonates. Expert Rev Clin Pharmacol 2017;10:239-42. [PMID: 28067058 DOI: 10.1080/17512433.2017.1279968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Kishimoto K, Hasegawa D, Irie K, Okada A, Nakamura S, Tamura A, Yamamoto N, Kozaki A, Saito A, Ishida T, Fukushima S, Kosaka Y. Pharmacokinetic analysis for model‐supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Allegaert K, Fanos V, van den Anker JN, Laër S. Perinatal pharmacology. Biomed Res Int 2014;2014:101620. [PMID: 24822175 DOI: 10.1155/2014/101620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Van Donge T, Mian P, Tibboel D, Van Den Anker J, Allegaert K. Drug metabolism in early infancy: opioids as an illustration. Expert Opin Drug Metab Toxicol 2018;14:287-301. [PMID: 29363349 DOI: 10.1080/17425255.2018.1432595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
94 Sage DP, Kulczar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Genet 2014;5:281. [PMID: 25221567 DOI: 10.3389/fgene.2014.00281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
95 Smits A, De Cock RF, Cossey V, Knibbe CA, Allegaert K. Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates? Biomark Med 2012;6:283-9. [PMID: 22731901 DOI: 10.2217/bmm.12.25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
96 Allegaert K, Langhendries JP, van den Anker JN. Educational paper: Do we need neonatal clinical pharmacologists. Eur J Pediatr. 2012;Epub ahead of print. [PMID: 22588521 DOI: 10.1007/s00431-012-1734-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
97 Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: Key considerations and current challenges. Advanced Drug Delivery Reviews 2014;73:102-26. [DOI: 10.1016/j.addr.2013.10.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 11.9] [Reference Citation Analysis]
98 Piana C, Danhof M, Della Pasqua O. Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV. Expert Opin Drug Metab Toxicol 2017;13:497-511. [PMID: 28043170 DOI: 10.1080/17425255.2017.1277203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
99 Allegaert K, van den Anker J. Pharmacokinetics and pharmacodynamics of intravenous acetaminophen in neonates. Expert Rev Clin Pharmacol. 2011;4:713-718. [PMID: 22111857 DOI: 10.1586/ecp.11.50] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
100 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 7.2] [Reference Citation Analysis]
101 Barker CI, Standing JF, Turner MA, McElnay JC, Sharland M. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough? Curr Opin Infect Dis 2012;25:235-42. [PMID: 22517604 DOI: 10.1097/QCO.0b013e328353105c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
102 Valkenburg AJ, de Leeuw TG, van Dijk M, Tibboel D. Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy? Paediatr Drugs 2015;17:339-48. [PMID: 26076801 DOI: 10.1007/s40272-015-0138-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
103 Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci 2017;109S:S22-6. [PMID: 28502674 DOI: 10.1016/j.ejps.2017.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
104 Zheng Y, Ye PP, Zhou Y, Wu SY, Liu XT, Du B, Tang BH, Kan M, Nie AQ, Yin R, Wang M, Hao GX, Song LL, Yang XM, Huang X, Su LQ, Wang WQ, van den Anker J, Zhao W. LPS-Induced Inflammation Affects Midazolam Clearance in Juvenile Mice in an Age-Dependent Manner. J Inflamm Res 2021;14:3697-706. [PMID: 34377007 DOI: 10.2147/JIR.S321492] [Reference Citation Analysis]
105 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Allegaert K. Pediatric clinical pharmacology: an introduction to a series of educational papers. Eur J Pediatr 2013;172:289-92. [DOI: 10.1007/s00431-012-1921-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Admiraal R, Boelens JJ. Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. Expert Opinion on Biological Therapy 2016;16:801-13. [DOI: 10.1517/14712598.2016.1164688] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
108 O'Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol 2015;80:1281-8. [PMID: 26256466 DOI: 10.1111/bcp.12741] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
109 van Schaick E, Benninga MA, Levine A, Magnusson M, Troy S. Development of a population pharmacokinetic model of prucalopride in children with functional constipation. Pharmacol Res Perspect 2016;4:e00236. [PMID: 27891230 DOI: 10.1002/prp2.236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
110 Michelet R, Dossche L, Van Herzeele C, Van Bocxlaer J, Vermeulen A, Vande Walle J; On behalf of the SAFE-PEDRUG consortium. Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. Eur J Clin Pharmacol 2018;74:297-305. [DOI: 10.1007/s00228-017-2386-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
111 Zisowsky J, Krause A, Dingemanse J. Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics 2010;2:364-88. [PMID: 27721363 DOI: 10.3390/pharmaceutics2040364] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
112 Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res 2011;28:797-811. [PMID: 21153913 DOI: 10.1007/s11095-010-0333-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
113 Roberts JK, Stockmann C, Balch A, Yu T, Ward RM, Spigarelli MG, Sherwin CMT, Anderson B. Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Paediatr Anaesth 2015;25:222-30. [DOI: 10.1111/pan.12575] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
114 Vermeulen E, van den Anker JN, Della Pasqua O, Hoppu K, van der Lee JH; Global Research in Paediatrics (GRiP). How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians. J Pharm Pharmacol 2017;69:439-47. [PMID: 27671925 DOI: 10.1111/jphp.12637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
115 Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, Spaans E, Fabriek BO, Sandman H, Grossouw D, Hanff LM, Janssen PJ, Koch BC, Tibboel D, de Wildt SN. Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. Clin Pharmacokinet 2014;53:1045-51. [PMID: 25227283 DOI: 10.1007/s40262-014-0176-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]